Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging

被引：207
作者：
Mosconi, Lisa [1 ]
Berti, Valentina [1 ,2 ]
Glodzik, Lidia [1 ]
Pupi, Alberto [2 ]
De Santi, Susan [1 ]
de Leon, Mony J. [1 ,3 ]
机构：
[1] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA
[2] Univ Florence, Dept Clin Neurophysiol, Nucl Med Unit, I-50121 Florence, Italy
[3] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
来源：
JOURNAL OF ALZHEIMERS DISEASE | 2010年 / 20卷 / 03期
关键词：
Amyloid-beta; cerebral metabolic rate of glucose (CMRglc); normal aging; positron emission tomography; preclinical detection; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH-COMPOUND-B; BRAIN GLUCOSE-METABOLISM; 2-YEAR FOLLOW-UP; GENETIC RISK; EARLY-ONSET; BETA; DEMENTIA; DEPOSITION;
D O I：
10.3233/JAD-2010-091504
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to subtle brain changes occurring in the preclinical stage of the disease. Early diagnostics is necessary to identify and treat at risk individuals before irreversible neuronal loss occurs. In vivo imaging has long been used to evaluate brain structural and functional abnormalities as predictors of future AD in non-demented persons. Prior to development of amyloid-beta (A beta) tracers for positron emission tomography (PET), the most widely utilized PET tracer in AD was 2-[18F]fluoro-2-Deoxy-D-glucose (FDG) PET. For over 20 years, FDG-PET has been used to measure cerebral metabolic rates of glucose (CMRglc), a proxy for neuronal activity, in AD. Many studies have shown that CMRglc reductions occur early in AD, correlate with disease progression, and predict histopathological diagnosis. This paper reviews reports of clinical and preclinical CMRglc reductions observed in association with genetic and non-genetic risk factors for AD. We then briefly review brain A beta PET imaging studies in AD and discuss the potential of combining symptoms-sensitive FDG-PET measures with pathology-specific A beta-PET to improve the early detection of AD.
引用
收藏
页码：843 / 854
页数：12
相关论文
共 107 条
[1]   Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease [J].
Agdeppa, ED ;
Kepe, V ;
Liu, J ;
Flores-Torres, S ;
Satyamurthy, N ;
Petric, A ;
Cole, GM ;
Small, GW ;
Huang, SC ;
Barrio, JR .
JOURNAL OF NEUROSCIENCE, 2001, 21 (24) :art. no.-RC189
[2]   Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease [J].
Anchisi, D ;
Borroni, B ;
Franceschi, M ;
Kerrouche, N ;
Kalbe, E ;
Beuthien-Beumann, B ;
Cappa, S ;
Lenz, O ;
Ludecke, S ;
Marcone, A ;
Mielke, R ;
Ortelli, P ;
Padovani, A ;
Pelati, O ;
Pupi, A ;
Scarpini, E ;
Weisenbach, S ;
Herholz, K ;
Salmon, E ;
Holthoff, V ;
Sorbi, S ;
Fazio, F ;
Perani, D .
ARCHIVES OF NEUROLOGY, 2005, 62 (11) :1728-1733
[3]   DISTRIBUTION OF ALZHEIMER-TYPE PATHOLOGICAL-CHANGES IN NONDEMENTED ELDERLY INDIVIDUALS MATCHES THE PATTERN IN ALZHEIMERS-DISEASE [J].
ARRIAGADA, PV ;
MARZLOFF, K ;
HYMAN, BT .
NEUROLOGY, 1992, 42 (09) :1681-1688
[4]   Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities [J].
Blass, JP .
NEUROBIOLOGY OF AGING, 2002, 23 (06) :1077-1084
[5]   Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis [J].
Braak, H ;
Braak, E .
ACTA NEUROPATHOLOGICA, 1996, 92 (02) :197-201
[6]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[7]   Forecasting the global burden of Alzheimer's disease [J].
Brookmeyer, Ron ;
Johnson, Elizabeth ;
Ziegler-Graham, Kathryn ;
Arrighi, H. Michael .
ALZHEIMERS & DEMENTIA, 2007, 3 (03) :186-191
[8]   Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (antDNA) [J].
Brown, AM ;
Sheu, RKF ;
Mohs, R ;
Haroutunian, V ;
Blass, JP .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2001, 16 (01) :41-48
[9]   Mild cognitive impairment -: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? [J].
Chételat, G ;
Desgranges, B ;
de la Sayette, V ;
Viader, F ;
Eustache, F ;
Baron, JC .
NEUROLOGY, 2003, 60 (08) :1374-1377
[10]   Evidence for an association between KIBRA and late-onset Alzheimer's disease [J].
Corneveaux, Jason J. ;
Liang, Winnie S. ;
Reiman, Eric M. ;
Webster, Jennifer A. ;
Myers, Amanda J. ;
Zismann, Victoria L. ;
Joshipura, Keta D. ;
Pearson, John V. ;
Hu-Lince, Diane ;
Craig, David W. ;
Coon, Keith D. ;
Dunckley, Travis ;
Bandy, Daniel ;
Lee, Wendy ;
Chen, Kewei ;
Beach, Thomas G. ;
Mastroeni, Diego ;
Grover, Andrew ;
Ravid, Rivka ;
Sando, Sigrid B. ;
Aasly, Jan O. ;
Heun, Reinhard ;
Jessen, Frank ;
Koelsch, Heike ;
Rogers, Joseph ;
Hutton, Michael L. ;
Melquist, Stacey ;
Petersen, Ron C. ;
Alexander, Gene E. ;
Caselli, Richard J. ;
Papassotiropoulos, Andreas ;
Stephan, Dietrich A. ;
Huentelman, Matthew J. .
NEUROBIOLOGY OF AGING, 2010, 31 (06) :901-909
12345678910